| human | Q5 |
| P734 | family name | Martin | Q12035675 |
| Martin | Q12035675 | ||
| Martin | Q12035675 | ||
| P735 | given name | Stacey | Q19826118 |
| Stacey | Q19826118 | ||
| P106 | occupation | researcher | Q1650915 |
| Q43046934 | Ability To Serologically Confirm Recent Zika Virus Infection in Areas with Varying Past Incidence of Dengue Virus Infection in the United States and U.S. Territories in 2016. |
| Q34556976 | Accuracy of real-time PCR, Gram stain and culture for Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae meningitis diagnosis |
| Q40454304 | An Assessment of the Cocooning Strategy for Preventing Infant Pertussis-United States, 2011. |
| Q45270716 | An overview of adverse events reported by participants in CDC's anthrax vaccine and antimicrobial availability program |
| Q52725898 | Assessment of Tdap Vaccination Effectiveness in Adolescents in Integrated Health-Care Systems. |
| Q42284930 | Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. |
| Q40054132 | Characteristics of Children Aged <18 Years with Zika Virus Disease Acquired Postnatally - U.S. States, January 2015-July 2016. |
| Q52589859 | Clinical evaluation and validation of laboratory methods for the diagnosis of Bordetella pertussis infection: Culture, polymerase chain reaction (PCR) and anti-pertussis toxin IgG serology (IgG-PT). |
| Q28297061 | Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis |
| Q55413867 | Detecting Local Zika Virus Transmission in the Continental United States: A Comparison of Surveillance Strategies. |
| Q51175319 | Early Impact of the US Tdap vaccination program on pertussis trends. |
| Q42246468 | Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial |
| Q51765282 | Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis. |
| Q38386808 | Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial |
| Q54286582 | Epidemiologic and laboratory features of a large outbreak of pertussis-like illnesses associated with cocirculating Bordetella holmesii and Bordetella pertussis--Ohio, 2010-2011. |
| Q84748753 | Estimating the effectiveness of acellular pertussis vaccines |
| Q46488763 | Evaluation of Commercial Assays for Single-Point Diagnosis of Pertussis in the US. |
| Q40673002 | Evaluation of Level of Agreement in Bordetella Species Identification in Three U.S. Laboratories during a Period of Increased Pertussis |
| Q23924129 | Evaluation of body mass index, pre-vaccination serum progesterone levels and anti-anthrax protective antigen immunoglobulin G on injection site adverse events following anthrax vaccination in women |
| Q42217708 | Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA human |
| Q64130262 | Factors influencing laboratory workers' decisions to accept or decline anthrax vaccine adsorbed (AVA): results of a decision-making study in CDC's anthrax vaccination program |
| Q43230753 | Health-related quality of life in the Anthrax Vaccination Program for workers in the Laboratory Response Network. |
| Q47365760 | Health-related quality of life in the CDC Anthrax Vaccine Adsorbed Human Clinical Trial. |
| Q40739286 | Impact of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccinations on Reported Pertussis Cases Among Those 11 to 18 Years of Age in an Era of Waning Pertussis Immunity: A Follow-up Analysis |
| Q46059421 | Impact of the US Maternal Tetanus, Diphtheria, and Acellular Pertussis Vaccination Program on Preventing Pertussis in Infants <2 Months of Age: A Case-Control Evaluation |
| Q43929104 | Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity |
| Q40201120 | Increased Risk for Meningococcal Disease among Men who have Sex with Men in the United States, 2012-2015. |
| Q44399415 | Increased incidence of meningococcal disease in HIV-infected individuals associated with higher case-fatality ratios in South Africa |
| Q40346821 | Meningococcal Carriage Evaluation in Response to a Serogroup B Meningococcal Disease Outbreak and Mass Vaccination Campaign at a College-Rhode Island, 2015-2016. |
| Q59431601 | Meningococcal Carriage Evaluation in Response to a Serogroup B Meningococcal Disease Outbreak and Mass Vaccination Campaign at a University—Oregon, 2015 |
| Q41926602 | Meningococcal Carriage Following a University Serogroup B Meningococcal Disease Outbreak and Vaccination Campaign with MenB-4C and MenB-FHbp - Oregon, 2015-2016. |
| Q47102654 | Meningococcal carriage among a university student population - United States, 2015. |
| Q38631851 | Meningococcal disease among men who have sex with men - United States, January 2012-June 2015. |
| Q34298066 | Molecular epidemiology of the pertussis epidemic in Washington State in 2012. |
| Q54331067 | National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. |
| Q41707535 | Pertactin-negative Bordetella pertussis strains: evidence for a possible selective advantage |
| Q37976390 | Pertussis Pseudo-outbreak linked to specimens contaminated by Bordetella pertussis DNA From clinic surfaces |
| Q30151997 | Pertussis Vaccine Effectiveness in the Setting of Pertactin-Deficient Pertussis |
| Q36148107 | Population diversity among Bordetella pertussis isolates, United States, 1935-2009 |
| Q47548936 | Population-Based Surveillance of Birth Defects Potentially Related to Zika Virus Infection - 15 States and U.S. Territories, 2016. |
| Q38158807 | Pregnancy Outcomes After Maternal Zika Virus Infection During Pregnancy - U.S. Territories, January 1, 2016-April 25, 2017. |
| Q107001865 | Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons |
| Q59431542 | Principles of Epidemiology and Public Health |
| Q54263777 | Qualitative assessment of pertussis diagnostics in United States laboratories. |
| Q40464630 | Recommendations for Use of Meningococcal Conjugate Vaccines in HIV-Infected Persons - Advisory Committee on Immunization Practices, 2016. |
| Q47748434 | Reduced Severity of Pertussis in Persons With Age-Appropriate Pertussis Vaccination-United States, 2010-2012. |
| Q80087194 | Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine |
| Q43320957 | Risk factors for Buruli ulcer disease (Mycobacterium ulcerans infection): Results from a case-control study in Ghana |
| Q44586740 | Serious adverse events among participants in the Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program for persons at risk for bioterrorism-related inhalational anthrax. |
| Q34346578 | Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data |
| Q40842298 | Serogroup B Meningococcal Disease Outbreak and Carriage Evaluation at a College - Rhode Island, 2015. |
| Q34516757 | Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae prior to introduction of the 10-valent pneumococcal conjugate vaccine in Brazil, 2000-2007 |
| Q57461949 | Severe Pertussis Infections in the United States, 2011-2015 |
| Q40564598 | Sources of Infant Pertussis Infection in the United States |
| Q36525266 | Sustained Transmission of Pertussis in Vaccinated, 1-5-Year-Old Children in a Preschool, Florida, USA. |
| Q41259190 | Tdap vaccine effectiveness in adolescents during the 2012 Washington State pertussis epidemic |
| Q40975616 | Trends in Pertussis Diagnostic Testing in the United States, 1990 to 2012. |
| Q38157323 | Update: Interim Guidance for Health Care Providers Caring for Pregnant Women with Possible Zika Virus Exposure - United States (Including U.S. Territories), July 2017. |
| Q38814254 | Update: Interim Guidance for Preconception Counseling and Prevention of Sexual Transmission of Zika Virus for Persons with Possible Zika Virus Exposure - United States, September 2016. |
| Q51336445 | Update: Noncongenital Zika Virus Disease Cases - 50 U.S. States and the District of Columbia, 2016. |
| Q64127509 | Uptake of pneumococcal conjugate vaccine among children in the 1998-2002 United States birth cohorts |
| Q40402876 | Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015. |
| Q38525922 | Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015. |
| Q39869724 | Vaccine effectiveness of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine during a pertussis outbreak in Maine |
| Q29168666 | Vital Signs: Update on Zika Virus–Associated Birth Defects and Evaluation of All U.S. Infants with Congenital Zika Virus Exposure — U.S. Zika Pregnancy Registry, 2016 |
| Q44792031 | Waning immunity to pertussis following 5 doses of DTaP. |
| Q58589277 | West Nile Virus and Other Nationally Notifiable Arboviral Diseases - United States, 2017 |
| Q39386989 | Zika Virus Disease Cases - 50 States and the District of Columbia, January 1-July 31, 2016. |
| Q78176630 | Zika Virus IgM 25 Months after Symptom Onset, Miami-Dade County, Florida, USA. |
| Q61053662 | Zika Virus IgM Detection and Neutralizing Antibody Profiles 12-19 Months after Illness Onset |
| Q28114568 | Zika Virus —10 Public Health Achievements in 2016 and Future Priorities |
Search more.